The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation

Structure

Volumn 13, Issue 6, 2005, Pages 861-871

  Cowan Jacob, Sandra W ^a   Fendrich, Gabriele ^a   Manley, Paul W ^a   Jahnke, Wolfgang ^a   Fabbro, Doriano ^a   Liebetanz, Janis ^a   Meyer, Thomas ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 METHYL 1 PIPERAZINYL)METHYL] N [3 [[4 (3 PYRIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ABELSON KINASE; BENZAMIDE DERIVATIVE; IMATINIB; METHYL GROUP; MYRISTIC ACID; PROTEIN SH2; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; BINDING SITES; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATION; HUMANS; HYDROGEN BONDING; HYDROPHOBICITY; INHIBITORY CONCENTRATION 50; LEUCINE; MODELS, CHEMICAL; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MYRISTIC ACID; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHOSPHORYLATION; PIPERAZINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SEQUENCE HOMOLOGY, AMINO ACID; SRC HOMOLOGY DOMAINS; SRC-FAMILY KINASES; TYROSINE;

EID: 20444399897     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2005.03.012     Document Type: Article

References (50)

1. S. Atwell, J.M. Adams, J. Badger, M.D. Buchanan, I.K. Feil, K. Ingeborg, K.J. Froning, X. Gao, J. Hendle, and K. Keegan A novel mode of gleevec binding is revealed by the structure of spleen tyrosine kinase J Biol Chem. 279 2004 55827 55832
2. T.J. Boggon, and M.J. Eck Structure and regulation of Src family kinases Oncogene 23 2004 7918 7927
3. R. Capdeville, E. Buchdunger, J. Zimmermann, and A. Matter Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nat. Rev. Drug Discov. 1 2002 493 502
4. CCP4 (Collaborative Computational Project, Number 4) The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
5. S.W. Cowan-Jacob, V. Guez, G. Fendrich, J.D. Griffin, D. Fabbro, P. Furet, J. Liebetanz, J. Mestan, and P.W. Manley Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment Mini Rev. Med. Chem. 4 2004 285 299
6. M.W.N. Deininger, J.M. Goldman, and J.V. Melo The molecular biology of chronic myeloid leukemia Blood 96 2000 3343 3356
7. B. Ellis Purification and characterization of deletional mutations of pp60c-src tyrosine kinase J. Cell. Biochem. 18B 1994 276
8. S. Faderl, M. Talpaz, Z. Estrov, and H.M. Kantarjian Chronic myelogenous leukemia: biology and therapy Ann. Intern. Med. 131 1999 207 219
9. S. Feng, J.K. Chen, H. Yu, J.A. Simon, and S.L. Schreiber Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions Science 266 1994 1241 1247
10. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P.N. Rao, and C.L. Sawyers Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
11. O. Hantschel, B. Nagar, S. Guettler, J. Kretzschmar, K. Dorey, J. Kuriyan, and G. Superti-Furga A myristoyl/phosphotyrosine switch regulates c-Abl Cell 112 2003 845 857
12. M. Harris, and T.A. Jones Molray: a web interface between O and the POV-Ray ray tracer Acta Crystallogr. D Biol. Crystallogr. 57 2001 1201 1203
13. S.C. Harrison Variation on an Src-like theme Cell 112 2003 737 740
14. C.M. Haystead, P. Gregory, T.W. Sturgill, and T.A. Haystead Gamma-phosphate-linked ATP-sepharose for the affinity purification of protein kinases: rapid purification to homogeneity of skeletal muscle mitogen-activated protein kinase kinase. Eur. J. Biochem. 214 1993 459 467
15. A. Hochhaus, and P. La Rosee Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance Leukemia 18 2004 1321 1331
16. S.R. Hubbard Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog EMBO J. 16 1997 5572 5581
17. T.P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M.L. Hensley, I. Gathmann, A.E. Bolton, I.C. van Hoomissen, and J.M. Goldman Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N. Engl. J. Med. 349 2003 1423 1432
18. P.D. Jeffrey, A.A. Russo, K. Polyak, E. Gibbs, J. Hurwitz, J. Massague, and N.P. Pavletich Mechanism of CDK activation revealed by the structure of a cyclin A-CDK2 complex Nature 376 1995 313 320
19. T.A. Jones, J.Y. Zou, S.W. Cowan, and M. Kjeldgaard Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallogr. A 47 1991 110 119
20. H.M. Kantarjian, J. Cortes, S. O'Brien, F.J. Giles, M. Albitar, M.B. Rios, J. Shan, S. Faderl, G. Garcia-Manero, and D.A. Thomas Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase Blood 99 2002 3547 3553
21. J. Kato, T. Takeya, C. Grandori, H. Iba, J.B. Levy, and H. Hanafusa Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein Mol. Cell. Biol. 6 1986 4155 4160
22. P.J. Kraulis MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures J. Appl. Crystallogr. 24 1991 945 949
23. M. LaFevre-Bernt, F. Sicheri, A. Pico, M. Porter, J. Kuriyan, and W.T. Miller Intramolecular regulatory interactions in the Src family kinase Hck probed by mutagenesis of a conserved tryptophan residue J. Biol. Chem. 273 1998 32129 32134
24. R.A. Laskowski, M.W. MacArthur, D.S. Moss, and J.M. Thornton PROCHECK: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 26 1993 283 291
25. E.C. Lerner, and T.E. Smithgall SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo Nat. Struct. Biol. 9 2002 365 369
26. I. Moarefi, M. LeFevre-Bernt, F. Sicheri, M. Huse, C.H. Lee, J. Kuriyan, and W.T. Miller Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement Nature 385 1997 650 653
27. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255
28. B. Nagar, W.G. Bornmann, P. Pellicena, T. Schindler, D.R. Veach, W.T. Miller, B. Clarkson, and J. Kuriyan Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 62 2002 4236 4243
29. B. Nagar, O. Hantschel, M.A. Young, K. Scheffzek, D. Veach, W. Bornmann, B. Clarkson, G. Superti-Furga, and J. Kuriyan Structural basis for the autoinhibition of c-Abl tyrosine kinase Cell 112 2003 859 871
30. T. O'hare, R. Pollock, E.P. Stoffregen, J.A. Keats, O.M. Abdullah, E.M. Moseson, V.M. Rivera, H. Tang, C.A. Metcalf III, and R.S. Bohacek Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML Blood 104 2004 2532 2539
31. M. Okada, and H. Nakagawa A protein tyrosine kinase involved in regulation of pp60c-src function J. Biol. Chem. 264 1989 20886 20893
32. A. Perrakis, T.K. Sixma, K.S. Wilson, and V.S. Lamzin wARP: improvement and extension of crystallographic phase by weighted averaging of multiple-refined dummy atomic models Acta Crystallogr. D Biol. Crystallogr. 53 1997 448 455
33. H. Pluk, K. Dorey, and G. Superti-Furga Autoinhibition of c-Abl Cell 108 2002 247 259
34. M.D. Resh Myristylation and palmitylation of Src family members: the fats of the matter Cell 76 1994 411 413
35. A.A. Russo, P.D. Jeffrey, and N.P. Pavletich Structural basis of cyclin-dependent kinase activation by phosphorylation Nat. Struct. Biol. 3 1996 696 700
36. P. Sairam, R. Puranik, A.S. Kelkar, S. Sasikiran, M. Veerender, and A. Parvathi The ester and amide derivatives of 4-(4-Methyl Piperazinomethyl) benzoic acid Synthetic Communications 33 2003 3597 3605
37. C.L. Sawyers Chronic myeloid leukemia N. Engl. J. Med. 340 1999 1330 1340
38. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 289 2000 1938 1942
39. T. Schindler, F. Sicheri, A. Pico, A. Gazit, A. Levitzki, and J. Kuriyan Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor Mol. Cell 3 1999 639 648
40. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 402
41. F. Sicheri, I. Moarefi, and J. Kuriyan Crystal structure of the Src family tyrosine kinase Hck Nature 385 1997 602 609
42. T.S. Ulmer, J.M. Werner, and I.D. Campbell SH3-SH2 domain orientation in Src kinases: NMR studies of Fyn Structure 10 2002 901 911
43. A. Vagin, and A. Teplyakov MOLREP: an automated program for molecular replacement J. Appl. Crystallogr. 30 1997 1022 1025
44. G. Waksman, D. Kominos, S.C. Robertson, N. Pant, D. Baltimore, R.B. Birge, D. Cowburn, H. Hanafusa, and B.J. Mayer Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides Nature 358 1992 646 653
45. M. Warmuth, R. Damoiseaux, Y. Liu, D. Fabbro, and N. Gray Src family kinases: potential targets for the treatment of human cancer and leukemia Curr. Pharm. Des. 9 2003 2043 2059
46. J.C. Williams, A. Weijland, S. Gonfloni, A. Thompson, S.A. Courtneidge, G. Superti-Furga, and R.K. Wierenga The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions J. Mol. Biol. 274 1997 757 775
47. W. Xu, A. Doshi, M. Lei, M.J. Eck, and S.C. Harrison Crystal structures of c-Src reveal features of its autoinhibitory mechanism Mol. Cell 3 1999 629 638
48. W. Xu, S.C. Harrison, and M.J. Eck Three-dimensional structure of the tyrosine kinase c-Src Nature 385 1997 595 602
49. H. Yamaguchi, and W.A. Hendrickson Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation Nature 384 1996 484 489
50. M.A. Young, S. Gonfloni, G. Superti-Furga, B. Roux, and J. Kuriyan Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation Cell 105 2001 115 126